Prices delayed by at least 15 minutes | Print
Wisdomtree Issuer Icav WISDOMTREE BIOREV UCITS ETF USD ACC (WBIO)
Open
1,410.40p
Previous close
1,406.50p
Trade high
1,446.20p
Income frequency
-
Year low
905.70p
Year high
1,506.20p
Replication method
Physical Full
Volume
19,204
Type
ETF
UCITS
Yes
Dividend yield
–
Ongoing charge
0.45
ISIN
IE000O8KMPM1
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Before investing please read:
Share price
Asset allocation
Top 10 holdings
| Holdings 18/12/2025 | % of assets |
|---|---|
| Eli Lilly and Co | 3.14 |
| Structure Therapeutics Inc ADR | 3.05 |
| Moderna Inc | 2.85 |
| Natera Inc | 2.85 |
| Stoke Therapeutics Inc | 2.79 |
| Johnson & Johnson | 2.76 |
| Pfizer Inc | 2.52 |
| United Therapeutics Corp | 2.46 |
| Regenxbio Inc | 2.46 |
| CRISPR Therapeutics AG | 2.24 |
Investment objective
The fund seeks to track the price and yield performance, before fees and expenses, of an Index that measures the performance of companies involved in the genetics and biotechnology sectors.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.
Asset class
ETFMorningstar ratingTM
Morningstar sustainability ratingTM
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.